
In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
Christopher Betz, PharmD, BCPS, FKSHP, FASHP, professor in the department of clinical and administrative sciences at Sullivan University College of Pharmacy, discusses what the role of the pharmacist is in acute coronary syndrome management with platelet aggregation inhibitors.
Christopher Betz, PharmD, BCPS, FKSHP, FASHP, professor in the department of clinical and administrative sciences at Sullivan University College of Pharmacy, discusses what the role of the pharmacist is in acute coronary syndrome management with platelet aggregation inhibitors.
This video was recorded at the 2015 American Society of Health-System Pharmacists Midyear Meeting.






